Cancer Markers in Preventative Screening: What They Can — and Cannot — Tell You

The word "cancer marker" carries enormous emotional weight. Used appropriately, these tests are powerful clinical tools. Used without context, they can produce both false reassurance and unnecessary alarm. Our goal here is clarity.

What tumour markers actually are

Tumour markers are proteins — or other biological substances — produced by cancer cells or by the body in response to cancer. Most also have physiological roles in healthy tissue and can be elevated by benign conditions. This is why no single tumour marker is a diagnostic test for cancer. What they provide, in the context of comprehensive screening, is a signal worth monitoring.

PSA — the most studied, most debated

PSA (Prostate-Specific Antigen) is produced by prostate cells, both normal and malignant. Elevated PSA warrants further investigation — but it is not synonymous with prostate cancer. It can be elevated by benign prostatic hyperplasia, prostatitis, and even vigorous exercise. The clinical value lies not in a single reading but in the trajectory: a rapidly rising PSA (PSA velocity) is a much stronger signal than an elevated but stable value. Swiss guidelines recommend PSA discussion with men from age 45 (earlier with family history). Most do not receive it unless they ask.

CA-125 — ovarian cancer and beyond

CA-125 is elevated in approximately 80% of advanced ovarian cancers — and is the primary reason for its inclusion in comprehensive screening for women. It is also elevated in endometriosis, fibroids, and benign ovarian cysts, which limits its specificity. Again, trajectory and context matter more than a single value.

CEA, AFP, CA 19-9

CEA (carcinoembryonic antigen) is associated with colorectal, lung, breast, and other cancers. AFP (alpha-fetoprotein) is a primary marker for hepatocellular carcinoma. CA 19-9 is associated with pancreatic and biliary cancers. None are diagnostic alone — all are valuable signals within a comprehensive clinical picture.

How Aeonix uses oncology markers

Our oncology panel is not a cancer diagnosis. It is a baseline — and a trend. Used annually within a subscription plan, these markers allow your physician to track longitudinal change rather than respond to a single isolated value. A CEA that doubles between your 2024 and 2025 screens is far more clinically significant than an elevated but stable value over three years.

That is the clinical intelligence that annual monitoring provides — and that a one-time check-up cannot.